Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Loading
Home›
Research›
People›
Douglas Crawford
AddedMar 31, 2024
UpdatedMay 31, 2026
Douglas Crawford

Douglas Crawford

Founder, MBC Biolabs

Crunchbase

Douglas Crawford's Career

MBC Biolabs
MBC Biolabs

San Francisco, CA, US

Founder
Mission Bay Capital
Mission Bay Capital

San Francisco, CA, US

Founder
Epiodyne
Epiodyne

San Francisco, CA, US

CEO· C-Suite · Management
Circle Pharma
Circle Pharma

San Francisco, CA, US

Board Member· Board

Create your profile now and gain access to exclusive deals and high-potential startups.

aVenture product preview
aVenture product preview
aVenture product preview

Douglas Crawford's Career

MBC Biolabs
MBC Biolabs
192013San Francisco, CA, US
Founder
Mission Bay Capital
Mission Bay Capital
Investment FirmInvestment Firm52009San Francisco, CA, US
Founder

Similar to Mission Bay Capital

Mission BioCapitalMission BioCapitalCambridge, MA, USest. 2009Mission BioCapitalCambridge, MA, US · est. 2009

Mission BioCapital: A life science venture capital firm fueling startups for positive change.

Investment Firm · $11M35
Bay City CapitalBay City CapitalSan Francisco, CA, USest. 1997Bay City CapitalSan Francisco, CA, US · est. 1997

Bay City Capital LLC: A seasoned investment management firm specializing in life sciences since 1997.

Investment Firm25
Bay PartnersBay PartnersMenlo Park, CA, USest. 1978Bay PartnersMenlo Park, CA, US · est. 1978

Bay Partners: A venture capital firm investing in IT and healthcare businesses.

Investment Firm5
Mission VenturesMission VenturesSan Diego, CA, USest. 1996Mission VenturesSan Diego, CA, US · est. 1996

Venture capital firm fostering Southern California's technology economy.

Investment Firm31
Epiodyne
Epiodyne
Series A$13.8M312016San Francisco, CA, US
CEO· C-Suite · Management

Leadership at Epiodyne

Aashish ManglikAashish ManglikCo-Founder
Peter GmeinerPeter GmeinerCo-Founder
Brian KobilkaBrian KobilkaCo-Founder
Bryan RothBryan RothCo-Founder

Similar to Epiodyne

EpiCypherEpiCypherThe Woodlands, TX, USBiotech Productsest. 2012EpiCypherThe Woodlands, TX, US · est. 2012

EpiCypher, a US-based bioscience pioneer, develops transformative epigenetics technologies for global researchers.

Angel · $140.3k66
BridGene BiosciencesBridGene BiosciencesSunnyvale, CA, USBiotech, Drug Discoveryest. 2018BridGene BiosciencesSunnyvale, CA, US · est. 2018

BridGene Biosciences: Innovating small molecule biotech for new disease treatment paths.

Series B · $50.5M23
SepternaSepternaSan Francisco, CA, USSmall Molecule Drugsest. 2022SepternaSan Francisco, CA, US · est. 2022

Septerna: A biotech firm pioneering novel small molecule medicines for future patient care.

Series B · $250M50
EpiBiologicsEpiBiologicsSan Mateo, CA, USTargeted Therapiesest. 2022EpiBiologicsSan Mateo, CA, US · est. 2022

EpiBiologics: Pioneering antibody-based therapies targeting disease-driving proteins.

Series A · $73M38
Circle Pharma
Circle Pharma
Series C$117.5M682012San Francisco, CA, US
Board Member· Board

Leadership at Circle Pharma

Peter SvennilsonPeter SvennilsonBoard Member
David J. EarpDavid J. EarpCEO
Walter H. MoosWalter H. MoosBoard Member
Thilo SchroederThilo SchroederBoard Member
John JoseyJohn JoseyBoard Member
Scott LokeyScott LokeyCo-Founder

Similar to Circle Pharma

20n Bio20n BioMalvern, PA, USPeptide Therapeuticsest. 202120n BioMalvern, PA, US · est. 2021

20n Bio, a VC-backed start-up in Malvern, PA, specializes in designing novel protein therapeutics.

Seed · $3.3M4
PeptilogicsPeptilogicsPittsburgh, PA, USPeptide Therapeuticsest. 2013PeptilogicsPittsburgh, PA, US · est. 2013

Peptilogics: An American biotech firm revolutionizing drug discovery with novel peptide therapeutics.

Series D · $44.1M28
Cyclo TherapeuticsCyclo TherapeuticsGainesville, FL, USBiotech, Treatmentsest. 1990Cyclo TherapeuticsGainesville, FL, US · est. 1990

Cyclo Therapeutics: A US-based clinical-stage biotech firm developing treatments for unmet medical needs.

Public · $16.8M9
Curie.BioCurie.BioBoston, MA, USDrug Developmentest. 2022Curie.BioBoston, MA, US · est. 2022

Curie.Bio: A seed-stage venture firm specializing in drug-focused services for founders.

Series B26

Douglas Crawford's Similar Executives & Operators

Soemantri BrodjonegoroSoemantri BrodjonegoroBoard Member · BukalapakJay Geoffrey WacherJay Geoffrey WacherBoard Member · BukalapakLau Eng BoonLau Eng BoonBoard Member · BukalapakNugroho HerucahyonoNugroho HerucahyonoCo-Founder · BukalapakWillix HalimWillix HalimCEO · BukalapakAchmad ZakyAchmad ZakyCo-Founder · BukalapakHaeil YiHaeil YiCo-Founder · DunamuLee Sirg-OoLee Sirg-OoCEO · Dunamu

People Similar to Douglas Crawford

Simba GillSimba GillFounder · MaxygenPeter BellPeter BellFounder · SSC Venture Partners